We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
Vesper Homes are a hybrid estate agents leading a rental revolution and aiming to save landlords and vendors an average of 50%. They are an expanding residential services company offering clients significantly lower fees and are looking to deploy a leading edge technology platform to improve services for both landlords and tenants. 
days to go: Expired investment: £121,371
Curious Projects have managed the Jones Family Project restaurant launched in November 2013 in Shoreditch. With a fun, friendly atmosphere they aim to source the best quality meat in the UK.
days to go: Expired investment: £241,820
WeTRAIN is a new way to have fun with personal training. They are the first shared personal training company and by doing this, they are creating a market of social exercise. WeTRAIN makes it easy for friends to have high quality, personalised training in a variety of different classes.
days to go: Expired investment: £437,138
The London Distillery Company (TLDC) is a producer of whiskies, gins and other amazing spirits. TLDC also produces a range of award-winning organic spirits under the 'Kew' and 'Dodd's' brands, with Kew being a unique collaboration with the Royal Botanic Gardens, Kew in London. TLDC exports to over 15 markets including China  while export to Canada and 6 South East Asian markets are still in progress. Since November 2017, sales volumes have increased by 44% to £864k in Mar 2019. TLDC is looking to expand the sales team to drive growth both in the UK and abroad. Furthermore, TLDC has had significant media coverage with the ITV, BBC and The Financial Times. Additionally, the company have plans to launch in the USA and India by the end of 2019.
days to go: Expired investment: £171,670
Solo Coffee is a company founded by Theo & Alex, aiming to simplify the world of specialty coffee. They've achieved £1.17 million in revenue for the financial year ending in April 2023 and break-even in March 2023 by producing espresso-strength cold brew coffee concentrate, which is used in various coffee applications, and they are now raising funds to support further growth in the rapidly growing Ready to Drink coffee market. Solo Coffee's Coffee Concentrate has gained popularity, with over 7 million servings sold since its launch in October 2020. It is used in numerous bars in the UK and is one of the top 3 most sold chilled coffees on Amazon UK. The company is expanding its manufacturing to the US and targeting various channels, including foodservice, on-trade, retail, and direct-to-consumer, to make coffee preparation easier in different settings.
days to go: Expired investment: £478,639
Integumen is a personal health company developing and commercialising technology and products for the human integumentary system that may improve physical appearance, hygiene and general health outcomes.
days to go: Expired investment: £2,160,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph